MARKET

CTIC

CTIC

CTi Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.040
-0.010
-0.33%
After Hours: 3.040 0 0.00% 16:14 09/24 EDT
OPEN
3.070
PREV CLOSE
3.050
HIGH
3.070
LOW
3.020
VOLUME
453.59K
TURNOVER
--
52 WEEK HIGH
4.130
52 WEEK LOW
1.000
MARKET CAP
283.66M
P/E (TTM)
-3.8340
1D
5D
1M
3M
1Y
5Y
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
/PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to twenty-five new employees as equity inducement awards outside of the Company...
PR Newswire - PRF · 09/17 20:05
CTI BioPharma to Get up to $135 Million in Funding From DRI Healthcare Trust
MT Newswires · 08/25 13:29
BRIEF-CTI Biopharma And DRI Healthcare Announce Up To $135 Mln Transaction
reuters.com · 08/25 11:33
CTI BioPharma Corp. And DRI Healthcare Trust Announce $135M In Debt And Royalty Transactions
CTI BioPharma Corp. (NASDAQ:CTIC) (CTI) and DRI Healthcare Trust (TSX:DHT) (TSX:DHT) (DRI) today announced transactions totaling up to $135 million in funding for CTI, with $50 million in secured debt
Benzinga · 08/25 11:04
Stonepine Capital Management, LLC Buys Amryt Pharma PLC, CTI BioPharma Corp, Chiasma Inc, Sells ...
GuruFocus News · 08/24 15:38
Ghost Tree Capital, LLC Buys RAPT Therapeutics Inc, Allogene Therapeutics Inc, Galapagos NV, ...
GuruFocus News · 08/23 19:38
Altium Capital Management LP Buys Xtant Medical Holdings Inc, Kaleyra Inc, CTI BioPharma Corp, ...
GuruFocus News · 08/17 18:38
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 08/09 12:09
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CTIC. Analyze the recent business situations of CTi Biopharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CTIC stock price target is 7.28 with a high estimate of 15.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 86
Institutional Holdings: 54.26M
% Owned: 58.15%
Shares Outstanding: 93.31M
TypeInstitutionsShares
Increased
18
14.31M
New
5
243.17K
Decreased
11
1.14M
Sold Out
10
3.50M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.09%
Pharmaceuticals & Medical Research
-1.00%
Key Executives
Non-Executive Chairman/Independent Director
Laurent Fischer
President/Chief Executive Officer/Director
Adam Craig
Chief Financial Officer/Executive Vice President/Secretary
David Kirske
Chief Operating Officer/Executive Vice President
Bruce Seeley
Director
Diane Parks
Non-Executive Independent Director
Michael Metzger
Non-Executive Independent Director
David Parkinson
Non-Executive Independent Director
Matthew Perry
Non-Executive Independent Director
Reed Tuckson
No Data
About CTIC
CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (IST), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

Webull offers kinds of CTI BioPharma Corp stock information, including NASDAQ:CTIC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTIC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTIC stock methods without spending real money on the virtual paper trading platform.